Neoadjuvant ed adjuvant treatment with interleukin-2 of oral cavity and oropharynx squamous cell carcinoma

This is a study set up to evaluate whether the disease-free interval and survival are extended when perilymphatic injections of recombinant IL-2 (rIL-2) are combined with routine surgery and radiotherapy in the treatment of patients with T2-4, N0-3, MO squamous cell carcinoma of the oral cavity and oropharynx. Patients are randomized to receive either rIL-2 inductive and adjuvant immunotherapy or standard therapy. A multivariate analysis (BMDP-LR) was carried out to analyze the presence and distribution of clinical and pathological prognostic factors. Disease-free and global survival were analyze using the Kaplan-Meier SPIL method (BMDP). We report here clinical findings on 191 patients.